Treatment of chronic plaque type psoriasis with systemic mycophenolate mofetil

Acta Medica Iranica

Volumn 44, Issue 6, 2006, Pages 383-386

  Akhyani, M ^a   Toosi, S ^a   Robati, R M ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Mycophenolate mofetil; Psoriasis; Systemic treatment

Indexed keywords

CALCIPOTRIOL; CORTICOSTEROID; DITHRANOL; EMOLLIENT AGENT; ETRETIN; KERATOLYTIC AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PSORALEN;

ADOLESCENT; ADULT; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CASE REPORT; CHRONIC DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LABORATORY TEST; LIVER FUNCTION TEST; LIVER TOXICITY; PSORIASIS VULGARIS; PUVA; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

EID: 34347270207     PISSN: 00446025     EISSN: 00446025     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Jones EL, Epinette WW, Hackney VC, Menendez L, Frost P. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol. 1975 Dec; 65(6):537-542.
2. Zhou Y, Rosenthal D, Dutz J, Ho V. Mycophenolate mofetil (CellCept) for psoriasis: a two-center, prospective, open-label clinical trial. J Cutan Med Surg. 2003 May-Jun; 7(3):193-197.
3. Geilen CC, Arnold M, Orfanos CE. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol. 2001 Mar; 144(3):583-586.
4. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol. 1987 Dec; 17(6):962-971.
5. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant. 1996 Feb; 10(1 Pt 2):77-84.
6. Tong DW, Walder BK. Widespread plaque psoriasis responsive to mycophenolate mofetil. Australas J Dermatol. 1999 Aug; 40(3):135-137.
7. Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol. 1997 Sep; 37(3 Pt 1):445-449.
8. Geilen CC, Orfanos-Boeckel H, Offermann G, Orfanos CE. [Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses]. Hautarzt. 2000 Feb; 51(2):63-69. German.
9. Haufs MG, Beissert S, Grabbe S, Schutte B, Luger TA. Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol. 1998 Jan; 138(1):179-181.
10. Geilen CC, Tebbe B, Garcia Bartels C, Krengel S, Orfanos CE. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil. Br J Dermatol. 1998 Jun; 138(6):1101-1102.
11. Grundmann-Kollmann M, Mooser G, Schraeder P, Zollner T, Kaskel P, Ochsendorf F, Boehncke WH, Kerscher M, Kaufmann R, Peter RU. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol. 2000 May; 42(5 Pt 1):835-837.